Literature DB >> 19949062

Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006.

Heather J Adam1, Lisa Louie, Christine Watt, Denise Gravel, Elizabeth Bryce, Mark Loeb, Anne Matlow, Allison McGeer, Michael R Mulvey, Andrew E Simor.   

Abstract

We describe the epidemiology of heterogeneously resistant Staphylococcus aureus (hVISA) identified in Canadian hospitals between 1995 and 2006. hVISA isolates were confirmed by the population analysis profiling-area under the curve method. Only 25 hVISA isolates (1.3% of all isolates) were detected. hVISA isolates were more likely to have been health care associated (odds ratio [OR], 5.1; 95% confidence interval [CI], 1.9 to 14.2) and to have been recovered from patients hospitalized in central Canada (OR, 3.0; 95% CI, 1.2 to 7.4). There has been no evidence of vancomycin "MIC creep" in Canadian strains of methicillin (meticillin)-resistant S. aureus, and hVISA strains are currently uncommon.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19949062      PMCID: PMC2812162          DOI: 10.1128/AAC.01316-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

Review 1.  Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods.

Authors:  Catherine Liu; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

2.  Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Benjamin P Howden; Paul D R Johnson; Peter B Ward; Timothy P Stinear; John K Davies
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Unstable vancomycin heteroresistance is common among clinical isolates of methiciliin-resistant Staphylococcus aureus.

Authors:  Nottasorn Plipat; Gilat Livni; Heidi Bertram; Richard B Thomson
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

4.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

Authors:  K Hiramatsu; N Aritaka; H Hanaki; S Kawasaki; Y Hosoda; S Hori; Y Fukuchi; I Kobayashi
Journal:  Lancet       Date:  1997-12-06       Impact factor: 79.321

5.  A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital.

Authors:  Fabien Garnier; Delphine Chainier; Timothy Walsh; Asa Karlsson; Anne Bolmström; Carole Grelaud; Marcelle Mounier; François Denis; Marie-Cécile Ploy
Journal:  J Antimicrob Chemother       Date:  2005-11-14       Impact factor: 5.790

6.  Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin.

Authors:  J Ariza; M Pujol; J Cabo; C Peña; N Fernández; J Liñares; J Ayats; F Gudiol
Journal:  Lancet       Date:  1999-05-08       Impact factor: 79.321

7.  Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period.

Authors:  Guiqing Wang; Janet F Hindler; Kevin W Ward; David A Bruckner
Journal:  J Clin Microbiol       Date:  2006-09-06       Impact factor: 5.948

8.  A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides.

Authors:  Mandy Wootton; Alasdair P MacGowan; Timothy R Walsh; Robin A Howe
Journal:  J Clin Microbiol       Date:  2006-11-15       Impact factor: 5.948

9.  Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Amir Khosrovaneh; Kathleen Riederer; Sajjad Saeed; M Shamse Tabriz; Amar R Shah; Michel M Hanna; Mamta Sharma; Leonard B Johnson; Mohammad G Fakih; Riad Khatib
Journal:  Clin Infect Dis       Date:  2004-04-14       Impact factor: 9.079

10.  High percentage of methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in The Netherlands.

Authors:  Arjanne Van Griethuysen; Annemarie Van 't Veen; Anton Buiting; Timothy Walsh; Jan Kluytmans
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

View more
  23 in total

1.  Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates.

Authors:  Sebastian J van Hal; Michael C Wehrhahn; Thelma Barbagiannakos; Joanne Mercer; Dehua Chen; David L Paterson; Iain B Gosbell
Journal:  J Clin Microbiol       Date:  2011-01-26       Impact factor: 5.948

2.  Antimicrobial susceptibilities of health care-associated and community-associated strains of methicillin-resistant Staphylococcus aureus from hospitalized patients in Canada, 1995 to 2008.

Authors:  Andrew E Simor; Lisa Louie; Christine Watt; Denise Gravel; Michael R Mulvey; Jennifer Campbell; Allison McGeer; Elizabeth Bryce; Mark Loeb; Anne Matlow
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

Review 3.  Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates.

Authors:  Sebastiaan J van Hal; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

4.  Characterization of methicillin-resistant Staphylococcus aureus isolates from patients with persistent or recurrent bacteremia.

Authors:  Henry Wong; Christine Watt; Sameer Elsayed; Michael John; Glen Johnson; Kevin Katz; Sigmund Krajden; Christine Lee; Tony Mazzulli; Krystyna Ostrowska; David Richardson; Baldwin Toye; Christie Vermeiren; Deborah Yamamura; Andrew E Simor
Journal:  Can J Infect Dis Med Microbiol       Date:  2014-03       Impact factor: 2.471

5.  Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method.

Authors:  Sarah W Satola; Monica M Farley; Karen F Anderson; Jean B Patel
Journal:  J Clin Microbiol       Date:  2010-11-03       Impact factor: 5.948

Review 6.  Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus.

Authors:  Andreas Ambrosch; Simone Haefner; Edward Jude; Ralf Lobmann
Journal:  Int Wound J       Date:  2011-08-23       Impact factor: 3.315

Review 7.  Antimicrobial heteroresistance: an emerging field in need of clarity.

Authors:  Omar M El-Halfawy; Miguel A Valvano
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

8.  Effects of storage on vancomycin and daptomycin MIC in susceptible blood isolates of methicillin-resistant Staphylococcus aureus.

Authors:  Franziska Ludwig; Becky Edwards; Timothy Lawes; Ian M Gould
Journal:  J Clin Microbiol       Date:  2012-08-01       Impact factor: 5.948

9.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Authors:  Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek
Journal:  Clin Infect Dis       Date:  2016-07-14       Impact factor: 9.079

10.  Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America.

Authors:  Betsy E Castro; Maritza Berrio; Monica L Vargas; Lina P Carvajal; Lina V Millan; Rafael Rios; Angie K Hernandez; Sandra Rincon; Paola Cubides; Erika Forero; An Dinh; Carlos Seas; Jose M Munita; Cesar A Arias; Jinnethe Reyes; Lorena Diaz
Journal:  J Antimicrob Chemother       Date:  2020-09-01       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.